1h Free Analyst Time
Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2019Speak directly to the analyst to clarify any post sales queries you may have.
Summary
Human Papillomavirus Protein E7 (E7) pipeline Target constitutes close to 44 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes. The latest report Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2019, outlays comprehensive information on the Human Papillomavirus Protein E7 (E7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Human Papillomavirus Protein E7 (E7) - Human Papilloma Virus (HPV) E7 protein belongs to a group of proteins called oncoproteins. It plays a role in viral genome replication by driving entry of quiescent cells into the cell cycle. E7 protein has both transforming and trans-activating activities. It induces the disassembly of the E2F1 transcription factor from RB1, with subsequent transcriptional activation of E2F1-regulated S-phase genes. Ii interferes with host histone deacetylation mediated by HDAC1 and HDAC2, leading to transcription activation. It plays an important role in the inhibition of both antiviral and antiproliferative functions of host inteferon alpha. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 9, 4, 1, 11 and 2 respectively. Similarly, the universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 4, 7 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health, Infectious Disease and Gastrointestinal which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN), Head And Neck Cancer Squamous Cell Carcinoma, Anal Cancer, Oropharyngeal Cancer, Head And Neck Cancer, Human Papillomavirus Infections, Penile Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Vaginal Cancer, Vulvar Cancer, Anal Dysplasia, Glioblastoma Multiforme (GBM), Lung Cancer, Melanoma, Non-Small Cell Lung Carcinoma, Pancreatic Cancer, Rectal Cancer and Triple-Negative Breast Cancer (TNBC).
Furthermore, this report also reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
- The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E7 (E7)
- The report reviews Human Papillomavirus Protein E7 (E7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics and enlists all their major and minor projects
- The report assesses Human Papillomavirus Protein E7 (E7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Human Papillomavirus Protein E7 (E7) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E7 (E7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E7 (E7) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
IntroductionReport Coverage
Human Papillomavirus Protein E7 (E7) - Overview
Human Papillomavirus Protein E7 (E7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Human Papillomavirus Protein E7 (E7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Human Papillomavirus Protein E7 (E7) - Companies Involved in Therapeutics Development
Abion Inc
Advaxis Inc
AstraZeneca Plc
Bioleaders Corp
BioNTech SE
Cellid Co Ltd
Cue Biopharma Inc
Etubics Corp
Genexine Inc
Hookipa Pharma Inc
iBio Inc
Immunomic Therapeutics Inc
IMV Inc
Innovene
Inovio Pharmaceuticals Inc
Oxford Vacmedix UK Ltd
Papivax LLC
Selecta Biosciences Inc
Touchlight Genetics Ltd
Transgene SA
UbiVac LLC
ViciniVax BV
Vir Biotechnology Inc
VLP The Vaccines Company SL
Human Papillomavirus Protein E7 (E7) - Drug Profiles
(bizalimogene ralaplasmid + mavilimogene ralaplasmid) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABI-231 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABN-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies to Inhibit E7 for HPV Associated Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Human Papillomavirus Protein E7 (E7) - Dormant Products
Human Papillomavirus Protein E7 (E7) - Discontinued Products
Human Papillomavirus Protein E7 (E7) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Abion Inc, H2 2019
Pipeline by Advaxis Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Bioleaders Corp, H2 2019
Pipeline by BioNTech SE, H2 2019
Pipeline by Cellid Co Ltd, H2 2019
Pipeline by Cue Biopharma Inc, H2 2019
Pipeline by Etubics Corp, H2 2019
Pipeline by Genexine Inc, H2 2019
Pipeline by Hookipa Pharma Inc, H2 2019
Pipeline by iBio Inc, H2 2019
Pipeline by Immunomic Therapeutics Inc, H2 2019
Pipeline by IMV Inc, H2 2019
Pipeline by Innovene, H2 2019
Pipeline by Inovio Pharmaceuticals Inc, H2 2019
Pipeline by Oxford Vacmedix UK Ltd, H2 2019
Pipeline by Papivax LLC, H2 2019
Pipeline by Selecta Biosciences Inc, H2 2019
Pipeline by Touchlight Genetics Ltd, H2 2019
Pipeline by Transgene SA, H2 2019
Pipeline by UbiVac LLC, H2 2019
Pipeline by ViciniVax BV, H2 2019
Pipeline by Vir Biotechnology Inc, H2 2019
Pipeline by VLP The Vaccines Company SL, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019
List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abion Inc
- Advaxis Inc
- AstraZeneca Plc
- Bioleaders Corp
- BioNTech SE
- Cellid Co Ltd
- Cue Biopharma Inc
- Etubics Corp
- Genexine Inc
- Hookipa Pharma Inc
- iBio Inc
- Immunomic Therapeutics Inc
- IMV Inc
- Innovene
- Inovio Pharmaceuticals Inc
- Oxford Vacmedix UK Ltd
- Papivax LLC
- Selecta Biosciences Inc
- Touchlight Genetics Ltd
- Transgene SA
- UbiVac LLC
- ViciniVax BV
- Vir Biotechnology Inc
- VLP The Vaccines Company SL
